Chungja P Yoon

US Patent:

20070020237, Jan 25, 2007

Filed:

May 30, 2006

Appl. No.:

11/443575

Inventors:

Chungja Yoon - Rockville MD, US
Ji-Won Yoon - Rockville MD, US
Jaeseok Han - Lake Bluff IL, US

International Classification:

C12N 5/08
A61K 48/00
C12N 15/86

US Classification:

424093200, 435456000, 435366000

Abstract:

The invention provides an isolated tissue specific glucose responsive promoter having a polymerase binding domain 3′ to at least one tripartite transcription factor binding cis element having a hepatocyte nuclear factor-1 (HNF-1) element, a CAAT/enhancer binding protein (C/EBP) response element and a glucose-response element (GRE). The promoter can include a second or third tripartite transcription factor binding cis element. A host cell including the tissue specific glucose responsive promoter of the invention also are provided. Further provided is a method of treating or preventing diabetes. The method includes administering to an individual an effective amount of a viral particle having a vector comprising a tissue specific glucose responsive promoter comprising a polymerase binding domain 3′ to at least one tripartite transcription factor binding cis element having a hepatocyte nuclear factor-1 (HNF-1) element, a CAAT/enhancer binding protein (C/EBP) response element and a glucose-response element (GRE) operationally linked to an insulin encoding nucleic acid, wherein expression of the insulin encoding nucleic acid is tissue specific and glucose responsive.

US Patent:

20070124827, May 31, 2007

Filed:

Oct 10, 2006

Appl. No.:

11/545167

Inventors:

Ji-Won Yoon - Rockville MD, US
Chungja Yoon - Rockville MD, US

Assignee:

Biotech Institute for International Innovation, Inc. - Kyonggi-do

International Classification:

A01K 67/027

US Classification:

800018000

Abstract:

The invention provides a T2D mouse comprising a progeny from mating a C57BL/6 mouse and a DBA/2 mouse and exhibiting a blood glucose level of at least about 200 mg/dl, wherein the mouse is a non-human mammalian model predictive of human type 2 diabetes. The T2D mouse also can exhibit impairment of glucose tolerance, normal or increased insulin production, impaired adipocyte or muscle glucose transport or decreased expression of at least one polypeptide involved in insulin action. Further provided is a method of producing a non-human mammal predictive of type 2 diabetes. The method includes mating a C57BL/6 mouse with a DBA/2 mouse, and backing crossing offspring of the mating with a parental DBA/2 mouse to produce a progeny exhibiting a blood glucose level of at least about 200 mg/dl that is predictive of human type 2 diabetes. A method of screening for a therapeutic agent for use in treating type 2 diabetes also is provided. The method includes: (a) administering a compound to the mouse of claim and (b) screening the mouse for a reduced symptom of type 2 diabetes, thereby identifying a therapeutic agent for use in treating type 2 diabetes.